https://orcid.org/0000-0002-9160-6846
References
- Pistollato F, Ohayon EL, Lam A, et al. Alzheimer disease research in the 21st century: past and current failures, new perspectives and funding priorities. Oncotarget. 2016;7(26):38999–39016.
- Godman B, Haque M, Leong T, et al. The current situation regarding Long-Acting insulin analogues including biosimilars among African, Asian, European, and South American countries; findings and implications for the future. Front Public Health. 2021;9:636.
- Jawed I, Wilkerson J, Prasad V, et al. Colorectal cancer survival gains and novel treatment regimens: a systematic review and analysis. JAMA Oncol. 2015;1(6):787–795.
- Jakovljevic M, Sugahara T, Timofeyev Y, et al. Predictors of (in) efficiencies of healthcare expenditure among the leading Asian economies–comparison of OECD and non-OECD nations. RMHP. 2020;13:2261–2280.
- Ogura S, Jakovljević M. Health financing constrained by population aging: an opportunity to learn from Japanese experience. Serbian J Exp Clin Res. 2014;15(4):175–181.
- Jakovljevic M, Cerda AA, Liu Y, et al. Sustainability challenge of Eastern Europe—historical legacy, belt and road initiative, population aging and migration. Sustainability. 2021;13(19):11038.
- Szalavetz A. Artificial intelligence-based development strategy in dependent market economies–any room amidst big power rivalry? CEBR. 2019;8(4):40–54.
- Yu Z, Liang Z, Wu P. How data shape actor relations in artificial intelligence innovation systems: an empirical observation from China. Ind Corporate Change. 2021;30(1):251–267.
- Calamia M, McBride A, Abraham I. Economic evaluation of polatuzumab-bendamustine-rituximab vs tafasitamab-lenalidomide in transplant-ineligible R/R DLBCL. J Med Econ. 2021;24(sup1):14–24.
- Obeng-Kusi M, Habila MA, Roe DJ, et al. Economic evaluation using dynamic transition modeling of ebola virus vaccination in lower-and-middle-income countries. J Med Econ. 2021;24(sup1):1–13.
- Abraham I, Onyekweree U, Denize B, et al. Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy. J Med Econ. 2021. DOI:https://doi.org/10.1080/13696998.2021.2014163.
- Choi BM, Abraham RB, Halawah H, et al. Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities. J Med Econ. 2021;24(sup1):34–41.
- Chen G, Sharifa B, Gerbera B, et al. Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada. J Med Econ. 2021;24(sup1):51–59.
- Alam K, Schofield D. Economic evaluation of genomic sequencing in the paediatric population: a critical review. Eur J Hum Genet. 2018;26(9):1241–1247.
- Jakovljevic J, Liu Y, Cerda AA, et al. The global south political economy of health financing and spending landscape – history and presence. J Med Econ. 2021;24(sup1):25–33.
- Grech S. Recolonising debates or perpetuated coloniality? Decentring the spaces of disability, development and community in the global South. Int J Inclusive Educ. 2011;15(1):87–100.
- Jakovljevic J, Wu W, Merrick J, et al. Asia-Pacific innovation in pharmaceutical and medical device industry – beyond tomorrow.
- Li Z-Z, Liu G, Tao R, et al. Do health expenditures converge among ASEAN countries? Front Public Health. 2021;9:1133.
- Jakovljevic M, Jakab M, Gerdtham U, et al. Comparative financing analysis and political economy of noncommunicable diseases. J Med Econ. 2019;22(8):722–727.
- Hughes VS, De Azeredo-Da ALF, Hincapie AL. Health economics and outcomes research knowledge needs assessment for Latin America. Value Health Reg Issues. 2019;20:2–6.